gms | German Medical Science

63rd Annual Meeting of the German Society of Neurosurgery (DGNC)
Joint Meeting with the Japanese Neurosurgical Society (JNS)

German Society of Neurosurgery (DGNC)

13 - 16 June 2012, Leipzig

MACC1 expression correlates with human malignant glioma progression and unfavourable patient's prognosis

Meeting Abstract

  • C. Hagemann - Neurochirurgische Universitätsklinik, Tumorbiologisches Labor, Universitätsklinikum Würzburg
  • S. Fuchs - Neurochirurgische Universitätsklinik, Tumorbiologisches Labor, Universitätsklinikum Würzburg
  • C.M. Monoranu - Universität Würzburg, Pathologisches Institut, Neuropathologie
  • R.I. Ernestus - Neurochirurgische Universitätsklinik, Tumorbiologisches Labor, Universitätsklinikum Würzburg
  • G.H. Vince - Neurochirurgische Universitätsklinik, Tumorbiologisches Labor, Universitätsklinikum Würzburg
  • U. Stein - Experimetelles und klinisches Forschungszentrum, eine Cooperation der Medizinischen Fakultät der Charité und des Max-Delbrück-Zentrums für Molekulare Medizin, Berlin

Deutsche Gesellschaft für Neurochirurgie. Japanische Gesellschaft für Neurochirurgie. 63. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC), Joint Meeting mit der Japanischen Gesellschaft für Neurochirurgie (JNS). Leipzig, 13.-16.06.2012. Düsseldorf: German Medical Science GMS Publishing House; 2012. DocFR.01.12

doi: 10.3205/12dgnc176, urn:nbn:de:0183-12dgnc1769

Published: June 4, 2012

© 2012 Hagemann et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( You are free: to Share – to copy, distribute and transmit the work, provided the original author and source are credited.



Objective: Metastasis-associated in colon cancer-1 (MACC1) was found to be upregulated in colon cancer tissue compared to normal tissues and has been established as an independent prognostic indicator of metastasis formation and metastasis-free survival for colon cancer patients. It has also been reported to be upregulated in gastric, lung and hepatocellular carcinomas. However, no data are available concerning MACC1 expression in human astrocytic tumors. Glioblastoma multiforme (GBM) are the most prevalent brain tumors of adults and due to their invasive and rapid growth patients have a very low prognosis. GBM may appear de novo without known precursor-lesion (primary GBM) or progress from low grade astrocytomas (secondary GBM). Although these tumors rarely metastasize, their invasive and migratory behavior is similar to those of metastatic cells of tumors with different origin. Thus, we hypothesized that MACC1 may be involved in progression of human gliomas.

Methods: Expression of MACC1 has been analysed by semiquantitative and quantitative RT-PCR in a panel of 8 astrocytoma WHO grade II (LGA), 15 GBM and 3 normal brain biopsies. Immunohistochemistry was performed with matched samples of 24 LGA and 14 GBM (10 primary and 4 secondary GBM). MACC1 expression correlated with tumor grade, recurrence of disease and patients survival. Finally, real-time measurements (xCELLigence) of migration and proliferation were performed in MACC1-overexpressing U138 cells.

Results: MACC1 expression increased concomitantly with increasing WHO grading on mRNA- and protein-level. Analysis of MACC1 expression strength by immunohistochemistry allowed discrimination of dormant and recurrent LGA and of primary and secondary GBM. Strong MACC1 expression was associated with a reduced median patients survival. Finally, we found that MACC1 overexpression promoted proliferation and migration of U138 GBM cells.

Conclusions: MACC1 may be a new progression marker for human gliomas and a new therapeutic target for inhibition of their proliferation and migration.